DrugPatentWatch Database Preview
Drugs in Development Information for Tanespimycin
» See Plans and Pricing
What is the development status for investigational drug Tanespimycin?
Tanespimycin is an investigational drug.
There have been 33 clinical trials for Tanespimycin.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2008.
The most common disease conditions in clinical trials are Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, and Lymphoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bristol-Myers Squibb, and Memorial Sloan Kettering Cancer Center.
Summary for Tanespimycin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 3,859 |
| WIPO Patent Applications | 1,710 |
| Japanese Patent Applications | 1,844 |
| Clinical Trial Progress | Phase 3 (2008-02-01) |
| Vendors | 41 |
Recent Clinical Trials for Tanespimycin
| Title | Sponsor | Phase |
|---|---|---|
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer | National Cancer Institute (NCI) | Phase 2 |
| A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | Bristol-Myers Squibb | Phase 3 |
| Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Tanespimycin
Top disease conditions for Tanespimycin
Top clinical trial sponsors for Tanespimycin
US Patents for Tanespimycin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
